CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that two late-breaking presentations describing new long-term data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC) will be featured on November 12, 2018 during The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA (November 9-13, 2018).
Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPAR) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH).
The first presentation, abstract LB-3, titled ‘Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study’ will be delivered by Professor Chris Bowlus, MD, Division Chief of Gastroenterology and Hepatology, University of California at Davis Health. The 52-week analysis from this ongoing Phase 2 study may provide some insight into the primary efficacy outcome of the upcoming pivotal Phase 3 seladelpar PBC study. The Phase 3 primary efficacy outcome is a composite responder rate measured at 52 weeks that comprises an alkaline phosphatase
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.